We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Pharming Group N.V. Sponsored ADR (PHAR - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Pharming Group N.V. Sponsored ADR is a member of our Medical group, which includes 1186 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Pharming Group N.V. Sponsored ADR is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for PHAR's full-year earnings has moved 102.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, PHAR has returned 39.4% so far this year. Meanwhile, stocks in the Medical group have lost about 16% on average. This means that Pharming Group N.V. Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is POINT Biopharma Global Inc. . The stock has returned 21.6% year-to-date.
For POINT Biopharma Global Inc. the consensus EPS estimate for the current year has increased 67.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Pharming Group N.V. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 561 individual companies and currently sits at #53 in the Zacks Industry Rank. On average, this group has lost an average of 16.7% so far this year, meaning that PHAR is performing better in terms of year-to-date returns. POINT Biopharma Global Inc. is also part of the same industry.
Pharming Group N.V. Sponsored ADR and POINT Biopharma Global Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Pharming Group N.V. Sponsored ADR (PHAR - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Pharming Group N.V. Sponsored ADR is a member of our Medical group, which includes 1186 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Pharming Group N.V. Sponsored ADR is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for PHAR's full-year earnings has moved 102.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, PHAR has returned 39.4% so far this year. Meanwhile, stocks in the Medical group have lost about 16% on average. This means that Pharming Group N.V. Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is POINT Biopharma Global Inc. . The stock has returned 21.6% year-to-date.
For POINT Biopharma Global Inc. the consensus EPS estimate for the current year has increased 67.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Pharming Group N.V. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 561 individual companies and currently sits at #53 in the Zacks Industry Rank. On average, this group has lost an average of 16.7% so far this year, meaning that PHAR is performing better in terms of year-to-date returns. POINT Biopharma Global Inc. is also part of the same industry.
Pharming Group N.V. Sponsored ADR and POINT Biopharma Global Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.